Positive SMC Recommendation for Third Dose Cohort in Phio’s Clinical Study of PH-762

December 19, 2024

DENVER, Colo., Dec 19, 2024 (247marketnews.com)- Phio Pharmaceuticals (NASDAQ: PHIO) reported that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio’s Phase 1b clinical trial to assess PH-762’s safety and tolerability in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma, following PH-762’s encouraging safety profile in second cohort.

“Safety and efficacy data from our clinical trial continues to be encouraging as we develop PH-762 for the treatment of cutaneous carcinomas. We look forward to continued enrollment in the clinical study,” stated Mary Spellman MD, Phio’s acting Chief Medical Officer.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (PHIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.